Skip to main content
SpringerLink
Log in

Psychoneuroimmunologische Grundlagen psychischer Erkrankungen

  • Chapter
  • First Online:
Psychiatrie, Psychosomatik, Psychotherapie

Part of the book series: Springer Reference Medizin ((SRM))

  • 35k Accesses

Zusammenfassung

Psychische Erkrankungen weisen eine komplexe Pathophysiologie auf, die bis heute nur ansatzweise geklärt ist. Neben Veränderungen von Neurotransmittersystemen und Rezeptoren als deren Effektorsysteme, die dann auf nachgeschaltete Signaltransduktionsprozesse einwirken, mehren sich Hinweise, dass immunologische Mechanismen eine wichtige Rolle in der Pathophysiologie psychischer Erkrankungen spielen. Mittlerweile gibt es auch erste Ansätze, die versuchen, derartige Mechanismen im Sinne von neuartigen Therapiestrategien nutzbar zu machen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Ader R, Felten DL (1991) Psychoneuroimmunology. Academic, San Diego/New York/Toronto

    Google Scholar 

  • Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179–185

    Article  PubMed  Google Scholar 

  • Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611

    Article  CAS  PubMed  Google Scholar 

  • Alonso R, Chaudieu I, Diorio J, Krishnamurthy A, Quirion R, Boksa P (1993) Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells. J Neurochem 61:1284–1290

    Article  CAS  PubMed  Google Scholar 

  • Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, MacKinnon A, McGorry PD, Berger GE (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154

    Article  CAS  PubMed  Google Scholar 

  • Araujo DM, Lapchak PA, Chabot JG, Nair NP, Quirion R (1989) Characterization and possible role of growth factor and lymphokine receptors in the regulation of cholinergic function in the mammalian brain. Prog Clin Biol Res 317:423–436

    CAS  PubMed  Google Scholar 

  • Arolt V, Rothermundt M, Wandinger KP, Kirchner H (2000) Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5:150–158

    Article  CAS  PubMed  Google Scholar 

  • Avgustin B, Wraber B, Tavcar R (2005) Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46:268–274

    PubMed  Google Scholar 

  • Baker GA, Santalo R, Blumenstein J (1977) Effect of psychotropic agents upon the blastogenic response of human t-lymphocytes. Biol Psychiatry 12:159–169

    CAS  PubMed  Google Scholar 

  • Balschun D, Wetzel W, del Ray A, Pitossi F, Schneider H, Zuschratter W, Besedovsky HO (2004) Interleukin-6: a cytokine to forget. FASEB J 18:1788–1790

    Article  CAS  PubMed  Google Scholar 

  • Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG (2010) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 44:321–330

    Article  CAS  PubMed  Google Scholar 

  • Benros ME, Mortensen PB, Eaton WW (2012) Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci 1262:56–66. doi:10.1111/j.1749-6632.2012.06638.x

    Article  PubMed  Google Scholar 

  • Benveniste EN (1992) Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 263:C1–C16

    Article  CAS  PubMed  Google Scholar 

  • Berrios GE, Quemada JI (1990) Depressive illness in multiple sclerosis. Clinical and theoretical aspects of the association. Br J Psychiatry 156:10–16

    Article  CAS  PubMed  Google Scholar 

  • Bertini S, Garattini R, Delgado P, Ghezzi P (1993) Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in m ice. Immunology 79:217–219

    CAS  PubMed  PubMed Central  Google Scholar 

  • Besedovsky H, del Rey A, Sorkin E, Dinarello CA (1986) Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233:652–654

    Article  CAS  PubMed  Google Scholar 

  • Braida D, Sacerdote P, Panerai AE, Bianchi M, Aloisi AM, Iosue S, Sala M (2004) Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav Brain Res 153:423–429

    Article  CAS  PubMed  Google Scholar 

  • Bresee C, Rapaport MH (2009) Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 12:861–865

    Article  CAS  PubMed  Google Scholar 

  • Bruce LC, Peebles AMS (1903) Clinical and experimental observations in catatonia. J Ment Sci 49:614–628

    Google Scholar 

  • Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26:643–652

    Article  CAS  PubMed  Google Scholar 

  • Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68:337–343

    Article  CAS  PubMed  Google Scholar 

  • Chittiprol S, Venkatasubramanian G, Neelakantachar N, Babu SV, Reddy NA, Shetty KT, Gangadhar BN (2010) Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. J Psychiatr Res 44:310–313

    Article  PubMed  Google Scholar 

  • Cumiskey D, Curran BP, Herron CE, O’Connor JJ (2007) A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology 52:1616–1623

    Article  CAS  PubMed  Google Scholar 

  • Dameshek W (1930) White blood cells in dementia praecox and dementia paralytietwa. Arch Neurol Psychiatry 24:855

    Google Scholar 

  • DeLisi LE, Goodman S, Neckers LM, Wyatt RJ (1982) An analysis of lymphocyte subpopulations in schizophrenic patients. Biol Psychiatry 17:1003–1009

    CAS  PubMed  Google Scholar 

  • DeLisi LE, Weber RJ, Pert CB (1985) Are there antibodies against brain in sera from schizophrenic patients? Review and prospectus. Biol Psychiatry 20:110–115

    Article  CAS  PubMed  Google Scholar 

  • Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293–300

    Article  CAS  PubMed  Google Scholar 

  • Denney DR, Stephenson LA, Penick EC, Weller RA (1988) Lymphocyte subclasses and depression. J Abnorm Psychol 97:499–502

    Article  CAS  PubMed  Google Scholar 

  • Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC (1984) Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res 11:83–89

    Article  CAS  PubMed  Google Scholar 

  • Frank MG, Baratta MV, Sprunger DB, Watkins LR, Maier SF (2007) Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav Immun 21:47–59

    Article  CAS  PubMed  Google Scholar 

  • Furukawa H, del Ray A, Monge-Arditi G, Besedovsky HO (1998) Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice. Ann N Y Acad Sci 840:117–122

    Article  CAS  PubMed  Google Scholar 

  • Gimeno D, Marmot MG, Singh-Manoux A (2008) Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 33:1322–1334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grosskopf A, Müller N, Malo A, Wank R (1998) Potential role for the narcolepsy- and multiple sclerosis-associated HLA allele DQB1*0602 in schizophrenia subtypes. Schizophr Res 30:187–189

    Article  CAS  PubMed  Google Scholar 

  • Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T (1999) Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33:407–418

    Article  CAS  PubMed  Google Scholar 

  • Häfner S, Baghai TC, Eser D, Schüle C, Rupprecht R, Bondy B, Bedarida G, von Schacky C (2008) C-reactive protein is associated with polymorphisms of the angiotensin-converting enzyme gene in major depressed patients. J Psychiatr Res 42:163–165

    Article  PubMed  Google Scholar 

  • Hampel H, Schwarz MJ, Kötter HU, Schneider C, Müller N (1996) Cell adhesion molecules in the central nervous system: significance and therapeutic perspectives in neuropsychiatric disorders. Drug News Perspect 9:69–81

    CAS  Google Scholar 

  • Hayley S, Wall P, Anisman H (2002) Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms. Eur J Neurosci 15:1061–1076

    Article  CAS  PubMed  Google Scholar 

  • Henneberg A, Riedl B, Dumke HO, Kornhuber HH (1990) T-lymphocyte subpopulations in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 239:283–284

    Article  CAS  PubMed  Google Scholar 

  • Herbert TB, Cohen S (1993) Depression and immunity: a meta-analytic review. Psychol Bull 113:472–486

    Article  CAS  PubMed  Google Scholar 

  • Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH (1997) Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A 94:1500–1505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Irwin M, Smith TL, Gillin JC (1987) Low natural killer cytotoxicity in major depression. Life Sci 41:2127–2133

    Article  CAS  PubMed  Google Scholar 

  • Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M (2004) T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A 101:8180–8185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Knight JG (1982) Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia. Lancet 2:1073–1076

    Article  CAS  PubMed  Google Scholar 

  • Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391

    Article  PubMed  Google Scholar 

  • Korte S, Arolt V, Peters M, Weitzsch C, Rothermundt M, Kirchner H (1998) Increased serum neopterin levels in acutely ill and recovered schizophrenic patients. Schizophr Res 32:63–67

    Article  CAS  PubMed  Google Scholar 

  • Kurtz G, Müller N (1994) The antiphospholipid syndrome and psychosis. Am J Psychiatry 151:1841–1842

    Article  CAS  PubMed  Google Scholar 

  • Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22:370–379

    Article  CAS  PubMed  Google Scholar 

  • Lapchak PA (1992) A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport 3:165–168

    Article  CAS  PubMed  Google Scholar 

  • Lehmann-Facius H (1939) Serologisch-analytische Versuche mit Liquores und Seren von Schizophrenen. Allg Z Psychiatrie 110:232–243

    Google Scholar 

  • Levy EM, Borrelli DJ, Mirin SM, Salt P, Knapp PH, Peirce C, Fox BH, Black PH (1991) Biological measures and cellular immunological function in depressed psychiatric inpatients. Psychiatry Res 36:157–167

    Article  CAS  PubMed  Google Scholar 

  • Lewandowski G, Hobbs MV, Bloom FE (1994) Alteration of intracerebral cytokine production in mice infected with herpes simplex virus types 1 and 2. J Neuroimmunol 55:23–34

    Article  CAS  PubMed  Google Scholar 

  • Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150:1408–1410

    Article  CAS  PubMed  Google Scholar 

  • Lieberman AP, Pitha PM, Shin HS, Shin ML (1989) Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A 86:6348–6352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38

    Article  CAS  PubMed  Google Scholar 

  • Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995a) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29:141–152

    Article  CAS  PubMed  Google Scholar 

  • Maes M, Bosmans E, Meltzer HY (1995b) Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci 245:172–178

    Article  CAS  PubMed  Google Scholar 

  • Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221–225

    Article  CAS  PubMed  Google Scholar 

  • McAllister CG, Rapaport MH, Pickar D, Paul SM (1989a) Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. Arch Gen Psychiatry 46:956–957

    Article  CAS  PubMed  Google Scholar 

  • McAllister CG, Rapaport MH, Pickar D, Podruchny TA, Christison G, Alphs LD, Paul SM (1989b) Increased numbers of CD5+ B lymphocytes in schizophrenic patients. Arch Gen Psychiatry 46:890–894

    Article  CAS  PubMed  Google Scholar 

  • McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152:1291–1297

    Article  CAS  PubMed  Google Scholar 

  • Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, Kaufmann WE, Vehmas A, Andreasson KI (2006) Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer’s disease in a sex-dimorphic pattern. Neuroscience 141:1149–1162

    Article  CAS  PubMed  Google Scholar 

  • Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14:1–10

    Article  CAS  PubMed  Google Scholar 

  • Miller AH, Lackner C (1989) Tricyclic antidepressants and immunity. In: Miller AH (Hrsg) Depressive disorders and immunity. American Psychiatric Press, Washington, DC, S 85–103

    Google Scholar 

  • Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166–6173

    Article  CAS  PubMed  Google Scholar 

  • Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159:2994–2999

    CAS  PubMed  Google Scholar 

  • Molholm HB (1942) Hyposensitivity to foreign protein in schizophrenic patients. Psychiatry Q 16:565–571

    Article  Google Scholar 

  • Müller N (1995) Psychoneuroimmunology: implications for the drug treatment of psychiatric disorders. CNS Drugs 4:125–140

    Article  Google Scholar 

  • Müller N (2013) Immunologische Behandlungsoptionen bei schizophrenen Störungen. Fortschr Neurol Psychiatr 82:210–219

    Google Scholar 

  • Müller N, Ackenheil M (1995a) Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 14:223–228

    Article  PubMed  Google Scholar 

  • Müller N, Ackenheil M (1995b) The immune system and schizophrenia. In: Leonard BE, Miller K (Hrsg) Stress, the immune system and psychiatry. Wiley, New York/Chichester, S 137–164

    Google Scholar 

  • Müller N, Ackenheil M (1998) Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22:1–33

    Article  PubMed  Google Scholar 

  • Müller N, Bechter K (2013) The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurol Psychiatry Brain Res 19:87–101

    Article  Google Scholar 

  • Müller N, Schwarz MJ (2007) The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neurol Transm 72:269–280

    Google Scholar 

  • Müller N, Schwarz MJ (2010) Immune System and Schizophrenia. Curr Immunol Rev 6:213–220

    Article  PubMed  PubMed Central  Google Scholar 

  • Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R (1991) Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res 37:147–160

    Article  PubMed  Google Scholar 

  • Müller N, Gizycki-Nienhaus B, Günther W, Meurer M (1992) Depression as a cerebral manifestation of scleroderma: immunological findings in serum and cerebrospinal fluid. Biol Psychiatry 31:1151–1156

    Article  PubMed  Google Scholar 

  • Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M (1997) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247:308–313

    Article  PubMed  Google Scholar 

  • Müller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R (1999) Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 156:634–636

    PubMed  Google Scholar 

  • Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029–1034

    Article  PubMed  Google Scholar 

  • Müller N, Riedel M, Dehning S, Spellmann I, Müller-Arends A, Cerovecki A et al (2004a) Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology 29:176

    Google Scholar 

  • Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M (2004b) COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254:14–22

    Article  PubMed  Google Scholar 

  • Müller N, Riedel M, Schwarz MJ, Engel RR (2005a) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:149–151

    Article  PubMed  Google Scholar 

  • Müller N, Schwarz MJ, Riedel M (2005b) COX-2 inhibition in schizophrenia: focus on clinical effects of celecoxib therapy and the role of TNF-alpha. In: Eaton WW (Hrsg) Medical and psychiatric comorbidity over the course of life. American Psychiatric Publishing, Washington, DC, S 265–276

    Google Scholar 

  • Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684

    Article  PubMed  CAS  Google Scholar 

  • Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M (2010) Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121:119–124

    Article  Google Scholar 

  • Müller N, Myint AM, Schwarz MJ (2012a) Immunological treatment options for schizophrenia. In: Mulert Ch, Scarr E (Hrsg) New treatment strategies in schizophrenia. Current Pharmaceutical Biotechnology 13:1606–1613

    Google Scholar 

  • Müller N, Myint AM, Schwarz MJ (2012b) Inflammation in schizophrenia. In: Donev R (Hrsg) Advances in protein chemistry and structural biology. Inflammation in psychiatric disorders. Oxford: Academic press, S 49–68

    Google Scholar 

  • Murr C, Widner B, Wirleitner B, Fuchs D (2002) Neopterin as a marker for immune system activation. Curr Drug Metab 3:175–187

    Article  CAS  PubMed  Google Scholar 

  • Na KS, Lee KJ, Lee JS, Cho YS, Jung HY (2013) Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 48:79–85. doi:10.1016/j.pnpbp.2013.09.006

    Article  PubMed  CAS  Google Scholar 

  • Nair A, Bonneau RH (2006) Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 171:72–85

    Article  CAS  PubMed  Google Scholar 

  • Nemni R, Iannaccone S, Quattrini A, Smirne S, Sessa M, Lodi M, Erminio C, Canal N (1992) Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res 591:248–252

    Article  CAS  PubMed  Google Scholar 

  • Nikkilä HV, Muller K, Ahokas A, Rimon R, Andersson LC (2001) Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res 49:99–105

    Article  PubMed  Google Scholar 

  • Nisticò G, De Sarro G (1991) Is interleukin 2 a neuromodulator in the brain? Trends Neurosci 14:146–150

    Article  PubMed  Google Scholar 

  • Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39(6):1230–1241

    Google Scholar 

  • Norris JG, Benveniste EN (1993) Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 45:137–145

    Article  CAS  PubMed  Google Scholar 

  • Ogawa A, Yoshizaki A, Yanaba K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S (2010) The differential role of L-selectin and ICAM-1 in Th1-type and Th2-type contact hypersensitivity. J Invest Dermatol 130:1558–1570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pennisi E (1997) Neuroimmunology. Tracing molecules that make the brain-body connection. Science 275:930–931

    Article  CAS  PubMed  Google Scholar 

  • Plata-Salaman CR (1991) Immunoregulators in the nervous system. Neurosci Biobehav Rev 15:185–215

    Article  CAS  PubMed  Google Scholar 

  • Pollmächer T, Hinze SD, Mullington J, Holsboer F (1995) Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors [letter]. Arch Gen Psychiatry 52:877–878

    Article  PubMed  Google Scholar 

  • Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D (2001) On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr Neurol Psychiatr 69(Suppl 2):S65–S74

    Article  PubMed  Google Scholar 

  • Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808

    Article  CAS  PubMed  Google Scholar 

  • Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748–752

    CAS  PubMed  Google Scholar 

  • Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D (2005) Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 57:1594–1596

    Article  CAS  PubMed  Google Scholar 

  • Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ, Müller N (2007) Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 41:3–7

    Article  PubMed  Google Scholar 

  • Ross BM, Seguin J, Sieswerda LE (2007) Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 6(21):21

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H (2001) Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 251:90–97

    Article  CAS  PubMed  Google Scholar 

  • Schennach H, Murr C, Gachter E, Mayersbach P, Schonitzer D, Fuchs D (2002) Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem 48:643–645

    CAS  PubMed  Google Scholar 

  • Schwarz MJ, Riedel M, Ackenheil M, Müller N (2000) Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 47:29–33

    Article  CAS  PubMed  Google Scholar 

  • Schwieler L, Erhardt S, Erhardt C, Engberg G (2005) Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 112:863–872

    Article  CAS  PubMed  Google Scholar 

  • Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G (2015) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia – significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133

    PubMed  PubMed Central  Google Scholar 

  • Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H (1996) Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 94:198–204

    Article  CAS  PubMed  Google Scholar 

  • Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR, Mirel DB, Kendler KS, Freedman R, Gejman PV (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460:753–757

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K (1995) Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 762:474–476

    Article  CAS  PubMed  Google Scholar 

  • Soliven B, Albert J (1992) Tumor necrosis factor modulates the inactivation of catecholamine secretion in cultured sympathetic neurons. J Neurochem 58:1073–1078

    Article  CAS  PubMed  Google Scholar 

  • Sommer IE, de Witte L, Begemann M, Kahn RS (2012) Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 73:414–419

    Article  CAS  PubMed  Google Scholar 

  • Song C, Leonard BE (1994) An acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med Sci Res 22:313–314

    CAS  Google Scholar 

  • Sparkman NL, Johnson RW (2008) Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation 15:323–330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spellberg B, Edwards JE Jr (2001) Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 32:76–102

    Article  CAS  PubMed  Google Scholar 

  • Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D (1993) Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 34:536–543

    Article  CAS  PubMed  Google Scholar 

  • Sperner-Unterweger B, Miller C, Holzner B, Widner B, Fleischhacker WW, Fuchs D (1999) Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Müller N (Hrsg) Psychiatry, psychoimmunology, and viruses. Springer, Wien/New York, S 115–119

    Chapter  Google Scholar 

  • Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St CD, Goldstein DB, Stefansson K, Collier DA (2009) Common variants conferring risk of schizophrenia. Nature 460:744–747

    CAS  PubMed  PubMed Central  Google Scholar 

  • Stevens JR (1988) Schizophrenia and multiple sclerosis. Schizophr Bull 14:231–241

    Article  CAS  PubMed  Google Scholar 

  • Swerdlow NR, van Bergeijk DP, Bergsma F, Weber E, Talledo J (2009) The effects of memantine on prepulse inhibition. Neuropsychopharmacology 34:1854–1864

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Syvälahti E, Eskola J, Ruuskanen O, Laine T (1985) Nonsuppression of cortisol in depression and immune function. Prog Neuropsychopharmacol Biol Psychiatry 9:413–422

    Article  PubMed  Google Scholar 

  • Varga G, Nippe N, Balkow S, Peters T, Wild MK, Seeliger S, Beissert S, Krummen M, Roth J, Sunderkotter C, Grabbe S (2010) LFA-1 contributes to signal I of T-cell activation and to the production of T(h)1 cytokines. J Invest Dermatol 130:1005–1012

    Article  CAS  PubMed  Google Scholar 

  • Wagner von Jauregg J (1926) Fieberbehandlung bei Psychosen. Wien Med Wochenschr 76:79–82

    Google Scholar 

  • Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246:279–284

    Article  CAS  PubMed  Google Scholar 

  • Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643:40–49

    Article  CAS  PubMed  Google Scholar 

  • Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, Varma AO (1979) Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 91:194–199

    Article  CAS  PubMed  Google Scholar 

  • Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS (1993) Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 133:2523–2530

    Article  CAS  PubMed  Google Scholar 

  • Zhu J, Bengtsson BO, Mix E, Thorell LH, Olsson T, Link H (1994) Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). Immunopharmacology 27:225–244

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Münchner Zentrum für Neurowissenschaften - Gehirn & Geist (MCN), Ludwig-Maximilians-Universität München, Nußbaumstr. 7, 80336, München, Deutschland

    Norbert Müller

Authors
  1. Norbert Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norbert Müller .

Editor information

Editors and Affiliations

  1. em. Direktor der Klinik für Psychiatrie und Psychotherapie, der Ludwig-Maximilians-Universität (LMU) München, München, Germany

    Hans-Jürgen Möller

  2. Ehem. Ärztlicher Direktor des kbo-Inn-Salzach-Klinikums für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Akadem. Lehrkrankenhaus der LMU München Institut für Psychologische Medizin (IPM), Soyen, Germany

    Gerd Laux

  3. Vorstand der Klinik für Psychiatrie und Psychotherapeutische Medizin, Medizinische Universität Graz, Graz, Austria

    Hans-Peter Kapfhammer

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Deutschland

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Müller, N. (2017). Psychoneuroimmunologische Grundlagen psychischer Erkrankungen. In: Möller, HJ., Laux, G., Kapfhammer, HP. (eds) Psychiatrie, Psychosomatik, Psychotherapie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49295-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49295-6_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49293-2

  • Online ISBN: 978-3-662-49295-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation